Aclairo Pharma Dev. Group specializes in providing comprehensive services in non-clinical pharmacology, toxicology, and drug development, with a strong emphasis on preclinical ADME (absorption, distribution, metabolism, excretion) and clinical pharmacology. Their team, composed of experienced scientists and regulatory experts, offers strategic guidance and operational support to facilitate the efficient progression of drug candidates from preclinical stages to clinical trials. Aclairo's services include the development and implementation of ADME/PK strategies, regulatory submissions, study monitoring, and data analysis, ensuring that clients navigate the complexities of drug development effectively.

In addition to their preclinical offerings, Aclairo also focuses on clinical pharmacology, providing services that encompass the entire spectrum of drug development. Their expertise includes pharmacokinetic modeling, bioanalytical assay implementation, and the assessment of drug-drug interactions. Aclairo's consultants conduct critical reviews and gap analyses of regulatory submissions, ensuring that development programs meet the necessary standards at various stages, including IND, EOP2, NDA, and CTD. By leveraging their extensive knowledge in both preclinical and clinical settings, Aclairo aims to optimize the drug development process and enhance the likelihood of successful regulatory interactions.

United States

Aclairo's experience as FDA supervisors, reviewers, and industry strategists has forged a unique comprehension of the product-specific complexities of pharmaceutical development. The Aclairo advantage is our experience-based approach to providing strategic, scientific and regulatory services. This has proven to be our greatest asset in focusing and streamlining our clients' development efforts, reducing both time and costs.

Aclairo Pharma Dev. Group

Company Details